Collaboration

Bioarctic and Lilly partner in neurodegeneration

Mon, 22 Jun 2026 09:00:00 -0400

Bioarctic AB has entered into a research and collaboration agreement with Eli Lilly and Co. on a new treatment in the field of neurodegeneration. The collaboration will see Bioarctic generate a new drug candidate combining its Braintransporter technology with an undisclosed Lilly molecule.

Constantiam and Cincinnati Children’s enter Gaucher collaboration

Fri, 19 Jun 2026 09:00:00 -0400

Constantiam Biosciences Inc. and Cincinnati Children’s have established a strategic collaboration, through an exclusive option for future licensing rights, to advance first-in-class small-molecule treatments for neuronopathic Gaucher disease (types 2 and 3).

Scenic Biotech joins MJFF LITE program to expand PLA2G15 research

Thu, 11 Jun 2026 09:00:00 -0400

Scenic Biotech BV has joined The Michael J. Fox Foundation for Parkinson’s Research (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE) program to explore the therapeutic potential of its PLA2G15 inhibitor program in Parkinson’s disease, including in patients carrying LRRK2 mutations.

Syntax Bio and Mayo Clinic partner in type 1 diabetes

Wed, 10 Jun 2026 09:00:00 -0400

Syntax Bio Inc. has established a research and development collaboration with Mayo Clinic focused on advancing stem cell-derived pancreatic cell therapies for type 1 diabetes.

Arvinas joins MJFF initiatives to advance LRRK2 research

Fri, 05 Jun 2026 09:00:00 -0400

Arvinas Inc. has joined the LRRK2 Investigative Therapeutics Exchange (LITE) program and the Parkinson’s Precision Medicine Initiative (PPMI), both supported by The Michael J. Fox Foundation for Parkinson’s Research (MJFF).

Xtalpi reports milestones under Dovetree collaboration

Mon, 01 Jun 2026 09:00:00 -0400

Xtalpi Inc.’s strategic collaboration with Dovetree Medicines Unus Inc. has made substantial progress, with Xtalpi receiving the second payment under the agreement.

CEPI supports Moderna’s vaccine against Bundibugyo Ebola virus

Mon, 01 Jun 2026 09:00:00 -0400

Moderna Inc. has announced an expanded collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a potential vaccine against Bundibugyo Ebola virus (BDBV), a cause of Ebola virus disease.

Innovent, Pfizer partner on 12 early-stage cancer programs

Fri, 29 May 2026 09:00:00 -0400

Innovent Biologics Inc. and Pfizer Inc. have entered into a strategic global licensing and collaboration agreement for the research and development of 12 new breakthrough early-stage and de novo cancer medicines.

Biomunex enters AI partnerships to advance cancer immunotherapies

Wed, 27 May 2026 09:00:00 -0400

Biomunex Pharmaceuticals SAS has entered into strategic collaborations with two AI-specialized companies – Gordion Bioscience Inc. and Tangramed Biotech SAS – as part of its strategy to integrate AI into its R&D activities and support the development of next-generation immunotherapies in oncology.

Circio and Aavigen to collaborate on targeted cardiac AAVs

Wed, 27 May 2026 09:00:00 -0400

Circio Holding ASA and Aavigen GmbH have entered a research collaboration focused on developing circVec-enhanced AAV vectors engineered for targeted, low-dose gene therapies for heart diseases.

Launch of CGTxchange to reactivate cell and gene therapy programs

Fri, 15 May 2026 09:00:00 -0400

The American Society of Gene & Cell Therapy (ASGCT) and Orphan Therapeutics Accelerator (OTXL) have announced the public launch of CGTxchange, an AI-enhanced clearinghouse and marketplace built to help reactivate cell and gene therapy programs that have been shelved despite strong scientific and clinical evidence.

Andzonbio2 enters neuroinflammation collaboration

Thu, 14 May 2026 09:00:00 -0400

Andzonbio2 has signed agreements with the Alborada Drug Discovery Institute (ADDI) at the University of Cambridge and Cambridge Enterprise to advance a new class of therapeutics targeting neuroinflammation, a central driver of multiple neurodegenerative and neurological conditions.

AOP Health and VRG Therapeutics partner on immunology program

Wed, 13 May 2026 09:00:00 -0400

AOP Orphan Pharmaceuticals GmbH (AOP Health) has established a strategic partnership with VRG Therapeutics Zrt to advance a novel Kv1.3 potassium channel inhibitor for use in inflammation and immunology indications.

UCB and Cancer Research UK enter new oncology alliance

Thu, 07 May 2026 09:00:00 -0400

UCB SA has entered into a new multiproject strategic alliance with Cancer Research UK and its innovation arm, Cancer Research Horizons, to advance a pipeline of novel investigational oncology candidates.

Apertura Gene Therapy and TSC Alliance partner on gene therapies

Wed, 06 May 2026 09:00:00 -0400

Apertura Gene Therapy LLC and the TSC Alliance have established a collaboration to advance gene therapy programs designed to treat tuberous sclerosis complex (TSC).

Elaaj Bio advances gene therapy for CDKL5 deﬁciency disorder

Wed, 06 May 2026 09:00:00 -0400

Elaaj Bio, a wholly owned subsidiary of the nonproﬁt Loulou Foundation, has entered into a partnership with Viralgen Vector Core SL to advance a gene therapy program for CDKL5 deﬁciency disorder.

Genomics and Greywolf partner in autoimmune diseases

Thu, 30 Apr 2026 09:00:00 -0400

Genomics Ltd. has established a strategic relationship with Grey Wolf Therapeutics Ltd. (Greywolf) to develop first-in-class treatments for autoimmune diseases.

Astrazeneca exercises option for Pinetree’s PTX-299

Thu, 30 Apr 2026 09:00:00 -0400

Astrazeneca plc has exercised an option under its collaboration with Pinetree Therapeutics Inc. to obtain an exclusive global license to develop and commercialize PTX-299, a first-in-class bispecific antibody degrader targeting EGFR. The option exercise triggers a $25 million payment to Pinetree.

Milestone in Atrium and BMS cardiovascular collaboration

Fri, 24 Apr 2026 09:00:00 -0400

Atrium Therapeutics Inc. has earned a $15 million development milestone payment from Bristol Myers Squibb Co. (BMS) for the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the companies’ ongoing collaboration.

Entos and L-CMD Research Foundation collaborate

Tue, 21 Apr 2026 09:00:00 -0400

Entos Pharmaceuticals Inc. has established a collaboration with the L-CMD Research Foundation with the aim of developing a curative therapy for LMNA-related congenital muscular dystrophy (L-CMD).

Biogen to use Alloy Therapeutics’ Anticlastic ASO platform

Wed, 08 Apr 2026 09:00:00 -0400

Alloy Therapeutics Inc. has entered into a collaboration and license agreement with Biogen Inc. for the use of Alloy’s Anticlastic ASO platform to accelerate the development of innovative oligonucleotide therapeutics.

Akari Therapeutics partners with Wuxi XDC on ADC payload

Tue, 07 Apr 2026 09:00:00 -0400

Akari Therapeutics plc has established a strategic partnership with Wuxi XDC Cayman Inc. to accelerate the development of Akari’s novel PH1 payload. Akari’s lead program, AKTX-101, is initially targeting metastatic urothelial cancer.

Insilico Medicine and Aska enter gynecological collaboration

Wed, 25 Mar 2026 09:00:00 -0400

Insilico Medicine Cayman Topco has established a strategic research collaboration with Aska Pharmaceutical Co. Ltd. to identify novel therapeutic targets for challenging gynecological conditions, including endometriosis, uterine fibroids and adenomyosis.

Insitro and Bristol Myers Squibb expand ALS collaboration

Tue, 24 Mar 2026 09:00:00 -0400

Insitro Inc. has expanded its strategic collaboration with Bristol Myers Squibb Co. to advance a broadened portfolio of therapeutic programs for amyotrophic lateral sclerosis (ALS).

Glyconex and Nippon Kayaku collaborate on GNX201-ADC

Tue, 24 Mar 2026 09:00:00 -0400

Glyconex Inc. has entered into a collaboration agreement with Nippon Kayaku Co. Ltd. to advance GNX201-ADC, a next-generation glycan-directed antibody-drug conjugate (ADC) candidate for the treatment of solid tumors.

New Danish research program targets α-synuclein in Parkinson’s

Mon, 23 Mar 2026 09:00:00 -0400

A new Danish research project focused on Parkinson’s disease has received funding from Innovation Fund Denmark. The DESYNA (Degradation of Extracellular α-SYNuclein Aggregates) project aims to develop a new therapy targeting α-synuclein, the accumulation of which is a key driver of Parkinson’s disease.

Alloy Therapeutics and Abbvie partner on antibody platform

Tue, 17 Mar 2026 09:00:00 -0400

Alloy Therapeutics Inc. has entered into an agreement with Abbvie Inc. to develop a new antibody platform to discover antibodies against targets that are difficult to address with current technologies.

Aptar and Covirix Medical collaborate on inhaled antivirals

Fri, 13 Mar 2026 09:00:00 -0400

Aptar Pharma, part of Aptargroup Inc., has established a technical collaboration with Covirix Medical Pty Ltd. under a letter of intent to develop inhaled antiviral treatments.

Newcelx partners with Eledon to advance NCEL-101

Mon, 09 Mar 2026 09:00:00 -0400

Newcelx Ltd. has entered into a collaborative research agreement with Eledon Pharmaceuticals Inc. with the aim of advancing its lead program, NCEL-101, for type 1 diabetes.

Zelluna, Etcembly partner on AI-enabled T-cell receptor engineering

Mon, 09 Mar 2026 09:00:00 -0400

Zelluna ASA has established a collaboration with Etcembly Ltd. that will focus on the engineering of high-affinity, tumor-specific T-cell receptors targeting KKLC1.